| Title | Author(s) | Year | View Count |
 | Telbivudine displays consistent antiviral efficacy across patient subgroups for the treatment of chronic hepatitis B: Results from the GLOBE study | Thongsawat, S; Lai, CL; Gane, E; Chao, G; Fielman, B; Brown, N; GLOBE Investigator Group, . | 2006 | 130 |
| Optimal virologic and clinical efficacy at one year is associated with maximal early HBV suppression in nucleoside-treated hepatitis B patients | Zeuzem, S; Lai, CL; Gane, E; Liaw, YF; Thongsawat, S; Wang, YM; Chen, Y; Heathcote, J; Rasenack, J; Bzowej, N; Naoumov, N; Chao, G; Fielman, B; Brown, N | 2006 | 117 |
| Phase III comparison of telbivudine vs lamivudine in HBeAg-positive patients with chronic hepatitis B: Efficacy, safety, and predictors of response at 1 year | Gane, E; Lai, CL; Liaw, YF; Thongsawat, S; Wang, YM; Cheng, Y; Heathcote, J; Rasenack, J; Bzowej, N; Naoumov, N; Chao, G; Fielman, B; Brown, N | 2006 | 120 |
| Phase III Comparison of Telbivudine vs Lamivudine in Patients with Chronic Hepatitis B: Efficacy, Safety, and Predictors of Response at 1 Year | Bzowej, N; Lai, CL; Gane, E; Liaw, Y; Thongsawat, S; Wang, Y; Chen, Y; Heathcote, J; Rasenack, J; Naoumov, N; Chao, G; Fielman, B; Brown, N | 2006 | 118 |
| Telbivudine (LdT) vs. lmivudine for chronic Hepatitis B: First-year results from the international phase III GLOBE trial | Lai, CL; Gane, E; Liaw, YF; Thongsawat, S; Wang, YM; Chen, Y; Heathcote, J; Rasenack, J; Bzowej, N; Naoumov, N; Chao, G; Fielman, B; Brown, N; and the GLOBE Study Group, . | 2005 | 155 |
| Maximal early HBV suppression is predictive of optimal virologic and clinical efficacy in nucleoside-treated hepatitis B patients: scientific observations from a large multinational trial (the GLOBE study) | Lai, CL; Gane, E; Liaw, YF; Thongsawat, S; Wang, YM; Chen, Y; Heathcote, J; Rasenack, J; Bzowej, N; Naoumov, N; Chao, G; Fielman, B; Brown, N; and the GLOBE Study Group, . | 2005 | 155 |
|
